- BAT maintains its full-year forecast for adjusted operating profit growth at a range of +1.5% to +2.5%.
- The performance is expected to be weighted towards the second half of the year.
- The company anticipates a return to profit growth in the US market.
- BAT is “closely monitoring” global macroeconomic policies but remains confident in meeting its guidance.
- The current investment recommendations for BAT include 10 buys, 5 holds, and 1 sell.
A look at British American Tobacco Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
British American Tobacco‘s long-term outlook seems promising based on Smartkarma Smart Scores. The company excels in dividend and momentum, scoring a 5 in both categories, indicating a strong performance in rewarding shareholders and a positive market sentiment. With a value, growth, and resilience score of 3 each, British American Tobacco shows stability and moderate growth potential. Overall, the company’s standing appears solid, especially in terms of providing consistent dividends and maintaining positive momentum in the market.
As a holding company for various tobacco manufacturing and selling entities, including cigarettes, cigars, and other tobacco products, British American Tobacco P.L.C. plays a significant role in the tobacco industry. The company’s emphasis on dividends and ongoing market momentum positions it well for the future. With a balanced approach to value, growth, and resilience, British American Tobacco seems poised to continue its operations successfully in the long run, catering to the demand for a variety of tobacco products.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
